There are no approved flaviviral therapies and the development of vaccines against flaviruses has the potential of being undermined by antibody-dependent enhanc
Background:Therapies to interrupt the progression of early coronavirus disease 2019(Covid-19)remain elusive.Among them,convalescent plasma administered to hospi
We are currently faced with the question of how the CoV-2 severity may change in the years ahead.Our analysis of immunological and epidemiological data on endem